Biosimilars

July 2014 | Volume 13 | Issue 7 | Editorials | 788 | Copyright © July 2014


Jerry Bagel MD

Psoriasis Treatment Center of Central New Jersey
East Windsor, NJ

efficacy profile is established via analytical and cellular data, not through efficacy data ie, not through clinical trials. Having said all this, the biotech industry may be erecting barriers to slow biosimilars into the marketplace. The name brand companies through name brand recognition may promote that with 30 years of experience their manufacturing processes are most trustworthy even if they decide to produce biosimilars. If they are truly comparable to the originator products, biosimilars offer the possibility of decreasing cost and offering more patient therapeutic benefits. The question to be answered is whether the analytical techniques employed can elucidate a comparable efficacy/safety profile to the originator.
In conclusion, many psoriasis sufferers do not have access to effective therapies because of high cost. Reducing the cost of biologics should increase patient access. As technology advances, analytic techniques should help provide an effective method to predict efficacy and safety of biosimilars prior to human use. Should biosimilars show comparable analysis to the originator insurance companies will likely enforce the use of biosimilars prior to approval of proprietary biologics.

Acknowlegments

Elise Nelson LPN helped with the preparartion of this article.

Disclosure

The author has not declared any relevant conflicts.

References

  1. Sampogna F, Chenn MM, Melchi CF et al. Italian Multipurpose Psoriasis Research on Vital Experiences (Study) Group. Br J Dermatol. 2006;154(2):325-331.
  2. Horn EJ, Fox KM, Patel V et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survery. J Am Acad Dermatol. 2007;57(6):957-962.
  3. Armstrong A, Robertson A, Wu J, Schupp C, Lebwohl M Undertreatment: Treatment Trends, and Treatment Dissatisfaction Among Psoriasis and Psoriatic Patients in the United States Findings from the NPF Surveys 2003-2011. JAMA Dermatol. 2013;149(10):1180-1185.
  4. Title VII: Improving Access to Innovative Medical Therapies. Subtitle A: Biologic Price Competition and Innovation (BPCIA) Provsions of the Patient Protection and Affordable Care Act (PPACA) <http://www.fda.gov/downloads/Drugs/
  5. Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the Nation’s Biosimilar Program NEJM 2011 365;(5) 385-388.
  6. Woodcock J, Griffin J, Behrman R et al. The FDA’s assessment of follow-on protein products: a historical perspective. Nat Rev Drug Discov. 2007;6:437-42.
  7. Berkowitz S, Engen J, Mazzeo J, Jones G. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nature. Reviews/ Drug Discovery 2012;(11) 527-540.
  8. Shiestl M, Stangler T, Torella C et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nature Biotechnol. 2011;29(4) 310-312.
  9. Weise M, Bielsky M-C, DeSmet K et al. Blood Online 10/23/2012; doi: 10.1182-2012-04-425-744.
  10. Yoo DH, Hrycaj P, Miranda P et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when co-administered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013 Published Online 21 May 2013
  11. Kay J, Smolen J. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis. 2013

AUTHOR CORRESPONDENCE

Jerry Bagel MDdreamacres@aol.com
Close Menu